|
CA1341351C
(en)
|
1988-09-06 |
2002-03-26 |
Marc D. Better |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
IL89490A0
(en)
*
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Chimeric antibodies directed against metal chelates
|
|
JP3739009B2
(ja)
*
|
1989-11-07 |
2006-01-25 |
俊雄 高橋 |
マウス抗体ｖ領域遺伝子断片およびその遺伝子断片を用いたキメラ抗体の調製方法
|
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
WO1992013077A1
(en)
*
|
1991-01-29 |
1992-08-06 |
Brigham And Women's Hospital |
A cDNA ENCODING THE TYPE I IODOTHYRONINE 5' DEIODINASE
|
|
US5272078A
(en)
*
|
1991-01-29 |
1993-12-21 |
Brigham And Women's Hospital |
CDNA encoding the type I iodothyronine 5'deiodinase
|
|
US20050196400A1
(en)
*
|
1991-05-06 |
2005-09-08 |
Xoma Technology Ltd. |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
US6749853B1
(en)
*
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US5877289A
(en)
*
|
1992-03-05 |
1999-03-02 |
The Scripps Research Institute |
Tissue factor compositions and ligands for the specific coagulation of vasculature
|
|
US6036955A
(en)
*
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
|
US6004555A
(en)
*
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
|
US6093399A
(en)
*
|
1992-03-05 |
2000-07-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
|
FR2724320B1
(fr)
*
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
|
US6440418B1
(en)
*
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
|
CA2257357C
(en)
*
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
|
US6420140B1
(en)
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
|
EP0966533B1
(en)
|
1997-02-07 |
2009-09-16 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Activity dependent neurotrophic factor iii (adnf iii)
|
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
US7033589B1
(en)
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
CA2330916C
(en)
|
1998-05-19 |
2011-04-05 |
Research Development Foundation |
Triterpene compositions and methods for use thereof
|
|
DE69937835T2
(de)
|
1998-09-24 |
2009-01-02 |
Promega Corp., Madison |
Antikörper für apoptosemarker und anwendungsverfahren
|
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
US20030143233A1
(en)
*
|
1999-06-07 |
2003-07-31 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US20030103948A1
(en)
*
|
1999-06-07 |
2003-06-05 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
|
EP1731531B1
(en)
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Multiple cytokine-antibody complexes
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
DE60122286T2
(de)
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
AU7522401A
(en)
*
|
2000-06-06 |
2001-12-17 |
Idec Pharma Corp |
Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
|
|
ES2288967T3
(es)
|
2000-06-29 |
2008-02-01 |
Merck Patent Gmbh |
Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
|
|
US20060148732A1
(en)
*
|
2000-11-17 |
2006-07-06 |
Gutterman Jordan U |
Inhibition of NF-kappaB by triterpene compositions
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
HUP0400284A3
(en)
|
2001-05-03 |
2012-09-28 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use thereof
|
|
ATE489103T1
(de)
*
|
2001-10-26 |
2010-12-15 |
Scripps Research Inst |
Gezielte thrombose durch gewebefaktor polypeptiden
|
|
PL206975B1
(pl)
|
2001-12-04 |
2010-10-29 |
Merck Patent Gmbh |
Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
EP2283868B1
(en)
|
2002-07-15 |
2016-03-30 |
Board of Regents, The University of Texas System |
Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
|
|
AU2003304411A1
(en)
|
2002-08-01 |
2005-03-07 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
|
RU2366664C2
(ru)
|
2002-12-17 |
2009-09-10 |
Мерк Патент Гмбх |
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
|
|
EP2397189B1
(en)
|
2003-11-14 |
2015-03-18 |
Brigham and Women's Hospital, Inc. |
Methods of modulating immunity
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
PL1706428T3
(pl)
*
|
2004-01-22 |
2010-02-26 |
Merck Patent Gmbh |
Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
|
|
CN101146554B
(zh)
|
2005-01-27 |
2012-10-10 |
加州大学评议会 |
中和肉毒杆菌神经毒素的治疗性单克隆抗体
|
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
|
JP2009521912A
(ja)
|
2005-12-30 |
2009-06-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
低減された免疫原性を有する抗ｃｄ１９抗体
|
|
EP2192922A4
(en)
|
2007-09-17 |
2010-09-29 |
Univ California |
INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
|
|
DK2219672T3
(en)
|
2007-11-09 |
2016-05-17 |
Peregrine Pharmaceuticals Inc |
The anti-VEGF antibody compositions and methods
|
|
EP2294183B1
(en)
|
2008-06-18 |
2015-12-16 |
The Texas A&M University System |
Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
|
|
CN102893154A
(zh)
|
2010-01-15 |
2013-01-23 |
加利福尼亚大学董事会 |
用于检测癌症的组合物和方法
|
|
AU2011207253B2
(en)
|
2010-01-20 |
2015-02-12 |
Merck Sharp & Dohme Corp. |
Anti-ILT5 antibodies and ILT5-binding antibody fragments
|
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
|
EP3848394A1
(en)
|
2010-04-09 |
2021-07-14 |
Critical Care Diagnostics, Inc. |
Soluble human st-2 antibodies and assays
|
|
WO2011135544A2
(en)
|
2010-04-29 |
2011-11-03 |
Nasvax Ltd. |
Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
|
|
JP5978212B2
(ja)
|
2010-08-24 |
2016-08-24 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
Ｈｉｖコアタンパク質に特異的な抗体及びその使用
|
|
US20120148559A1
(en)
|
2010-12-01 |
2012-06-14 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
US10842849B2
(en)
|
2011-02-28 |
2020-11-24 |
The Schepens Eye Research Institute, Inc. |
Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
|
WO2014093417A1
(en)
|
2012-12-12 |
2014-06-19 |
University Of Virginia Patent Foundation |
Compositions and methods for regulating erythropoiesis
|
|
WO2014151917A1
(en)
|
2013-03-14 |
2014-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
|
DK3383920T3
(da)
|
2015-11-30 |
2024-04-02 |
Univ California |
Levering af tumorspecifik nyttelast og immunaktivering ved hjælp af et humant antistof rettet mod et meget specifikt tumorcelleoverfladeantigen
|
|
US12049511B2
(en)
|
2016-11-10 |
2024-07-30 |
Fortis Therapeutics, Inc. |
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
|
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
|
MX2019010202A
(es)
|
2017-03-03 |
2019-10-02 |
Seattle Genetics Inc |
Compuestos que interactuan con glicano y metodos de uso.
|
|
CN108727494A
(zh)
*
|
2017-04-25 |
2018-11-02 |
成都贝爱特生物科技有限公司 |
一种靶向筛选外源基因双整合位点提高人c5单抗表达产量的方法
|
|
BR112020001255A2
(pt)
|
2017-07-21 |
2020-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
composições imunogênicas de neisseria meningitidis
|
|
EP3710482A4
(en)
|
2017-11-14 |
2021-08-18 |
University Of Virginia Patent Foundation |
COMPOSITIONS AND METHODS OF MANUFACTURING AND USE OF BISPECIFIC ANTIBODIES
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
US20210355199A1
(en)
|
2018-06-28 |
2021-11-18 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
KR20250156861A
(ko)
|
2019-05-21 |
2025-11-03 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
US12384832B2
(en)
|
2019-06-19 |
2025-08-12 |
Christopher Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
CN115151566A
(zh)
|
2019-11-15 |
2022-10-04 |
普利安特治疗公司 |
用于活化整合素的组合物和方法
|
|
CA3169827A1
(en)
|
2020-03-10 |
2021-09-16 |
Kunwar Shailubhai |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
|
JP2023529853A
(ja)
|
2020-06-17 |
2023-07-12 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
キメラ抗原受容体（ｃａｒ）ｔ細胞療法を増強するための組成物および方法
|
|
WO2022023566A2
(en)
|
2020-07-30 |
2022-02-03 |
Tiziana Life Sciences Plc |
Cd-3 antibodies for the treatment of coronavirus
|
|
JP2023534765A
(ja)
|
2020-08-07 |
2023-08-10 |
フォーティス セラピューティクス，インク． |
免疫複合体を標的とするｃｄ４６およびその使用方法
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
EP4323402A1
(en)
|
2021-04-14 |
2024-02-21 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
|
US20220332822A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
|
WO2023064942A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
|
WO2023086835A1
(en)
|
2021-11-09 |
2023-05-19 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
|
WO2025006737A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
|
|
WO2025040820A1
(en)
|
2023-08-23 |
2025-02-27 |
Granular Therapeutics Limited |
Anti-cd203c antibody conjugates and uses thereof
|
|
WO2025215252A1
(en)
|
2024-04-12 |
2025-10-16 |
Ensocell Ltd |
Therapeutic agents and methods for targeting myeloid cell subtypes
|